MedTrace Logo

A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension

NCT05362110 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 361

Last updated 2023-09-26

No results posted yet for this study

Summary

A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HCP1803 in patients with essential hypertension

Conditions

Interventions

DRUG

HCP1803-3

Take it once daily for 8 weeks orally.

DRUG

RLD2002

Take it once daily for 8 weeks orally.

DRUG

HPP2003-3

Placebo drug. Take it once daily for 8 weeks orally.

DRUG

HPP2004

Placebo drug. Take it once daily for 8 weeks orally.

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Principal Investigators

  • Moo-Yong Rhee, M.D., Ph.D. · Donggguk University Ilsan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-16
Primary Completion
2023-06-05
Completion
2023-06-05

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05362110 on ClinicalTrials.gov